Brought to you by 
Novartis gets nonexclusive rights to use Oxford’s LentiVector in oncology
02 Feb 2023
Executive Summary
Oxford BioMedica PLC (gene drug delivery and immunotherapy) licensed Novartis AG nonexclusive global rights to use its LentiVector lentiviral gene transfer platform in cancer applications.
Deal Industry
- Pharmaceuticals
- Services
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
-
Drug Delivery
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
- Immuno-Oncology
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Includes Royalty or Profit Split Information
- Manufacturing or Supply
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Novartis gets nonexclusive rights to use Oxford’s LentiVector in oncology
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice